Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Pfizer stops production of Corex cough syrup

The move follows a government notification banning over 344 drug combinations, which included fixed dose combination of chlopheniramine maleate and codeine syrup

Topics
Pfizer, Corex, Cough Syrup, Drug Combinations, Fixed Dose Combination, Chlopheniramine Maleate, Codeine

BS B2B Bureau  |  Mumbai 

Pfizer stops production of Corex cough syrup

Pfizer Ltd has decided to discontinue the production and sale of Corex cough syrup with immediate effect. The move has been triggered after the government of India issued a notification on March 10, 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of chlopheniramine maleate and codeine syrup with immediate effect. Through the notification the government has banned over 344 drug combinations after a panel of experts found that they had no therapeutic justification.
 
“Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex cough syrup. The company is exploring all available options at its disposal," said Pfizer in a BSE filing today.
 
The discontinuation of Corex, which recorded a sale of Rs 176 crores for the nine months from April-December 2015, is likely to have an adverse impact on the revenue and profitability of Pfizer Ltd.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, March 14 2016. 12:46 IST
RECOMMENDED FOR YOU

Pfizer stops production of Corex cough syrup

The move follows a government notification banning over 344 drug combinations, which included fixed dose combination of chlopheniramine maleate and codeine syrup

The move follows a government notification banning over 344 drug combinations, which included fixed dose combination of chlopheniramine maleate and codeine syrup Pfizer Ltd has decided to discontinue the production and sale of Corex cough syrup with immediate effect. The move has been triggered after the government of India issued a notification on March 10, 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of chlopheniramine maleate and codeine syrup with immediate effect. Through the notification the government has banned over 344 drug combinations after a panel of experts found that they had no therapeutic justification.
 
“Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex cough syrup. The company is exploring all available options at its disposal," said Pfizer in a BSE filing today.
 
The discontinuation of Corex, which recorded a sale of Rs 176 crores for the nine months from April-December 2015, is likely to have an adverse impact on the revenue and profitability of Pfizer Ltd.
image
Business Standard
177 22

Pfizer stops production of Corex cough syrup

The move follows a government notification banning over 344 drug combinations, which included fixed dose combination of chlopheniramine maleate and codeine syrup

Pfizer Ltd has decided to discontinue the production and sale of Corex cough syrup with immediate effect. The move has been triggered after the government of India issued a notification on March 10, 2016 prohibiting the manufacture for sale, sale and distribution of fixed dose combination of chlopheniramine maleate and codeine syrup with immediate effect. Through the notification the government has banned over 344 drug combinations after a panel of experts found that they had no therapeutic justification.
 
“Corex has a well-established efficacy and safety profile in India for more than 30 years and Pfizer makes every effort to maintain the highest standards of regulatory and quality compliance in the manufacture and distribution of Corex cough syrup. The company is exploring all available options at its disposal," said Pfizer in a BSE filing today.
 
The discontinuation of Corex, which recorded a sale of Rs 176 crores for the nine months from April-December 2015, is likely to have an adverse impact on the revenue and profitability of Pfizer Ltd.

image
Business Standard
177 22